Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
Chem Pharm Bull (Tokyo) ; 69(2): 199-202, 2021.
Article in English | MEDLINE | ID: mdl-33518602

ABSTRACT

The 13C-NMR spectral data for the 15-carbon flavonoid skeleton in eleven methoxyflavones isolated from Kaempferia parviflora (Zingiberaceae) were processed by principal component analysis (PCA). Based on the PCA score plots, the methoxyflavones were categorized into three groups according to their structural features. The cytotoxicities of the methoxyflavones toward 3T3-L1 murine preadipocyte cells were evaluated by 3-(4,5-dimethylthiazole-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTT) assay and found to differ according to structure. The relationship between the 13C-NMR chemical shifts of the methoxyflavones and their cytotoxicities was investigated using Pearson's correlation analysis. The 13C-NMR signal at C-10, a quaternary carbon, was correlated with cytotoxicity. Based on these results, a structural design which lowers the 13C-NMR chemical shift at C-10 would be important for the development of cytotoxic compounds. Although quantitative structure-activity and structure-property relationships are well established paradigms for predicting trends among a series of compounds, quantitative property-activity relationships have been relatively unstudied. This approach offers a new strategy for directing structure-activity relationship research.


Subject(s)
Carbon-13 Magnetic Resonance Spectroscopy , Flavones/chemistry , 3T3-L1 Cells , Animals , Cell Survival/drug effects , Flavones/pharmacology , Mice , Plant Extracts/chemistry , Principal Component Analysis , Structure-Activity Relationship , Zingiberaceae/chemistry , Zingiberaceae/metabolism
2.
J Vet Med Sci ; 81(1): 147-154, 2019 Jan 25.
Article in English | MEDLINE | ID: mdl-30464089

ABSTRACT

Currently, metabolic syndrome is a worldwide concern. Thus, it is imperative to understand the mechanism of metabolic syndrome by establishing various metabolic syndrome models. In this study, we used Hatano high-avoidance animals (HAA) and low-avoidance animals (LAA), both derived from Sprague-Dawley rats by selective breeding to determine high- or low-avoidance rates in shuttle-box active avoidance tests. HAA and LAA rats have some strain differences related to eating and appetite. Therefore, we determined whether Hatano rats could be used as a metabolic syndrome model. We compared food intake, body weights, blood pressure levels, plasma component levels, and fat contents between HAA and LAA rats. The HAA rats showed more active eating, higher blood pressure, higher percentage fat, and higher triglyceride levels than the LAA rats-these features correspond to some of the risk factors associated with metabolic syndrome. Our study suggests that HAA rats can be considered as a metabolic syndrome model by focusing on their feeding behavior, blood pressure levels, and percent body fat.


Subject(s)
Disease Models, Animal , Metabolic Syndrome , Rats, Inbred Strains , Animals , Avoidance Learning , Body Weight , Eating , Rats
3.
J Nat Med ; 72(3): 607-614, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29550915

ABSTRACT

5,7-Dimethoxyflavone (5,7-DMF), one of the major components of Kaempferia parviflora, has anti-obesity, anti-inflammatory, and antineoplastic effects. On the other hand, in vitro studies have reported that it directly inhibits the drug metabolizing enzyme family cytochrome P450 (CYP) 3As. In this study, its safety was evaluated from a pharmacokinetic point of view, based on daily ingestion of 5,7-DMF. Midazolam, a substrate of CYP3As, was orally administered to mice treated with 5,7-DMF for 10 days, and its pharmacokinetic properties were investigated. In the group administered 5,7-DMF, the area under the curve (AUC) of midazolam increased by 130% and its biological half-life was extended by approximately 100 min compared to the control group. Compared to the control group, 5,7-DMF markedly decreased the expression of CYP3A11 and CYP3A25 in the liver. These results suggest that continued ingestion of 5,7-DMF decreases the expression of CYP3As in the liver, consequently increasing the blood concentrations of drugs metabolized by CYP3As.


Subject(s)
Flavonoids/therapeutic use , Midazolam/therapeutic use , Animals , Flavonoids/pharmacology , Humans , Male , Mice , Midazolam/pharmacokinetics
4.
J Nat Med ; 72(1): 136-144, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28823024

ABSTRACT

Knee osteoarthritis (OA) is becoming more prevalent worldwide due to increases in the numbers of elderly and obese patients. Currently, pharmaceutical medicines used for the treatment of OA are for symptomatic therapy and therefore new therapeutic agents are needed. Kaempferia parviflora (KP) is a plant growing naturally in Southeast Asia and has various pharmacological effects including an anti-inflammatory effect, but no effect on OA has yet been reported. We therefore conducted a search for the effects KP and the active components of KP extract (KPE) exert on OA as well as its mechanism of action. Results from a study of KPE using the monoiodoacetic acid rat OA model revealed that KPE reduced the pain threshold and severity of osteoarthritic cartilage lesions. The mechanism of action and active components were then investigated using IL-1ß-treated human knee-derived chondrocytes. KPE, as well as 5,7-dimethoxyflavone and 5,7,4'-trimethoxyflavone, which are key constituents of KPE and highly absorbable into the body, reduced the expression of matrix metalloproteinases (MMPs), which are the main extracellular matrix enzymes that degrade collagen within cartilage. As mentioned above, KPE acted to suppress OA and 5,7-dimethoxyflavone and 5,7,4'-trimethoxyflavone were shown to be involved as part of KPE's mechanism that inhibits MMPs.


Subject(s)
Osteoarthritis, Knee/drug therapy , Zingiberaceae/chemistry , Animals , Humans , Male , Osteoarthritis, Knee/pathology , Rats , Rats, Wistar
5.
Biol Pharm Bull ; 39(7): 1137-43, 2016.
Article in English | MEDLINE | ID: mdl-27374289

ABSTRACT

Visceral obesity induces the onset of metabolic disorders such as insulin resistance and diabetes mellitus. Adipose tissue is considered as a potential pharmacological target for treating metabolic disorders. The fruit of Terminalia bellirica is extensively used in Ayurvedic medicine to treat patients with diseases such as diabetes mellitus. We previously investigated the effects of a hot water extract of T. bellirica fruit (TB) on obesity and insulin resistance in spontaneously obese type 2 diabetic mice. To determine the active ingredients of TB and their molecular mechanisms, we focused on adipocyte differentiation using mouse 3T3-L1 cells, which are widely used to study adipocyte physiology. We show here that TB enhanced the differentiation of 3T3-L1 cells to mature adipocytes and that one of the active main components was identified as gallic acid. Gallic acid (10-30 µM) enhanced the expression and secretion of adiponectin via adipocyte differentiation and also that of fatty acid binding protein-4, which is the target of peroxisome proliferator-activated receptor gamma (PPARγ), although it does not alter the expression of the upstream genes PPARγ and CCAAT enhancer binding protein alpha. In the PPARγ ligand assay, the binding of gallic acid to PPARγ was undetectable. These findings indicate that gallic acid mediates the therapeutic effects of TB on metabolic disorders by regulating adipocyte differentiation. Therefore, TB shows promise as a candidate for preventing and treating patients with metabolic syndrome.


Subject(s)
Adipocytes/drug effects , Adiponectin/metabolism , Gallic Acid/pharmacology , Plant Extracts/pharmacology , Terminalia , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/metabolism , Animals , Cell Differentiation/drug effects , Cell Survival/drug effects , Fruit , Gallic Acid/isolation & purification , Mice , PPAR gamma/genetics , PPAR gamma/metabolism , Plant Extracts/chemistry , Triglycerides/metabolism
6.
J Nat Med ; 70(1): 54-61, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26386971

ABSTRACT

We have previously reported the effects of Kaempferia parviflora (KP), including anti-obesity, preventing various metabolic diseases, and regulating differentiation of white adipose cells. In this study we used Tsumura, Suzuki, Obese Diabetes (TSOD) mice--an animal model of spontaneous obese type II diabetes--and primary brown preadipocytes to examine the effects of the ethyl acetate extract of KP (KPE) on brown adipose tissue, which is one of the energy expenditure organs. TSOD mice were fed with MF mixed with either KPE 0.3 or 1% for 8 weeks. Computed tomography images showed that whitening of brown adipocytes was suppressed in the interscapular tissue of the KPE group. We also examined mRNA expression of uncoupling protein 1 (UCP-1) and ß3-adrenalin receptor (ß3AR) in brown adipose tissue. As a result, mRNA expression of UCP-1 significantly increased in the KPE 1% treatment group, indicating that KPE activated brown adipose tissue. We then evaluated the direct effects of KPE on brown adipocytes using primary brown preadipocytes isolated from interscapular brown adipocytes in ICR mice. Triacylglycerol (TG) accumulation in primary brown preadipocytes was increased by KPE in a dose-dependent manner. Each mRNA expression of peroxisome proliferator-activated receptor γ (PPARγ), UCP-1, and ß3AR exhibited an upward trend compared with the control group. Moreover, some polymethoxyflavonoids (PMFs), the main compound in KP, also increased TG accumulation. This study therefore showed that KPE enhanced the thermogenesis effect of brown adipocytes as well as promoted the differentiation of brown adipocyte cells.


Subject(s)
Adipocytes/metabolism , Adipose Tissue, Brown/drug effects , Anti-Obesity Agents/pharmacology , Plant Extracts/pharmacology , Thermogenesis , Zingiberaceae/metabolism , Acetates/chemistry , Adipocytes/cytology , Adipocytes/drug effects , Adipose Tissue, Brown/cytology , Adipose Tissue, Brown/metabolism , Animals , Cell Differentiation/drug effects , Cells, Cultured , Diabetes Mellitus, Type 2/metabolism , Ion Channels/genetics , Mice , Mice, Inbred ICR , Mice, Obese , Mitochondrial Proteins/genetics , Obesity/metabolism , PPAR gamma/metabolism , RNA, Messenger/biosynthesis , Receptors, Adrenergic, beta-3/genetics , Tomography, X-Ray Computed , Triglycerides/metabolism , Uncoupling Protein 1
7.
J Nat Med ; 68(4): 668-76, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24838513

ABSTRACT

Salacia reticulata Wight (S. reticulata) is a herbal medicine used for treatment of early diabetes in Ayurvedic medicine. In previous reports, the extract of S. reticulata showed preventive effects on obesity and various metabolic disorders and a suppressive effect on differentiation in premature adipocytes. The aim of this research was to elucidate the therapeutic efficacy of the extract of S. reticulata on obesity and various metabolic disorders in 12-week-old TSOD mice with obesity and metabolic disorders and in mature 3T3-L1 adipocytes. In TSOD mice, S. reticulata therapy produced a reduction in body weight and mesenteric fat accumulation, an improvement in abnormal glucose metabolism, and an increase in adiponectin level in plasma. In addition, the mRNA expressions of hormone-sensitive lipase (HSL) and adiponectin were increased in mesenteric fat. In in vitro experiments, S. reticulata therapy produced suppression of intracellular triacylglycerol accumulation and enhancement of glycerol release into the medium in mature 3T3-L1 cells. The mRNA expressions of lipogenesis factor (peroxisome proliferator-activated receptor γ, lipoprotein lipase, CD36, and fatty acid binding protein 4) were down-regulated, while the expressions of lipolysis factor (adipose tissue triacylglycerol lipase and HSL) and adiponectin were up-regulated. Moreover, the extract of S. reticulata enhanced the expression of total AMP-activated protein kinase α (AMPKα) and phosphorylated AMPKα in mature adipocytes. These findings demonstrate that the extract of S. reticulata has therapeutic effects on obesity and metabolic disorders by enhancing lipogenesis genes and suppressing lipolysis genes through the activation of AMPKα in adipocytes.


Subject(s)
Obesity/drug therapy , Phytotherapy , Salacia , 3T3-L1 Cells , AMP-Activated Protein Kinases/metabolism , Adipocytes/metabolism , Adipogenesis/drug effects , Adiponectin/blood , Adiponectin/genetics , Adipose Tissue/metabolism , Animals , Blood Glucose/analysis , Body Weight , Cell Differentiation/drug effects , Glycerol/metabolism , Lipase/metabolism , Lipolysis , Male , Metabolic Diseases/drug therapy , Mice , Obesity/metabolism , RNA, Messenger/metabolism , Triglycerides/metabolism
8.
J Med Food ; 17(3): 374-83, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24588719

ABSTRACT

The metabolic syndrome is a major worldwide health care issue and a dominant risk factor for cardiovascular disease. The liver manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). Although significant research has been performed, the basic pathogenesis of NAFLD/NASH remains controversial and effective treatments are still unavailable. We have previously reported on a murine model of NASH induced by the neonatal injection of monosodium glutamate (MSG), which includes the clinical manifestations of central obesity, diabetes, hyperlipidemia, and ultimately liver inflammation, fibrosis, and cancer. Although MSG is considered a safe food additive, its administration to pregnant rats increases the voracity and growth hormone levels in the offspring. To further understand the biology of this model, we have investigated the influence of the calorie intake on these clinical manifestations by feeding animals a restrictive diet. MSG-treated animals fed a restrictive diet continue to manifest obesity and early stage NASH but have improvements in serum lipid profiles. At 12 months of age, mice had manifestations of obesity, whether animals were fed a restricted or control diet, but animals fed a restrictive diet had a reduction in the progression of NASH. In conclusion, MSG appears to be a critical factor in the initiation of obesity, whereas calorie intake may modulate the progression of disease.


Subject(s)
Obesity/diet therapy , Sodium Glutamate/adverse effects , Animals , Diet, Reducing , Disease Progression , Fatty Liver/diet therapy , Fatty Liver/etiology , Fatty Liver/metabolism , Fatty Liver/pathology , Humans , Male , Mice, Inbred ICR , Non-alcoholic Fatty Liver Disease , Obesity/complications , Obesity/metabolism , Sodium Glutamate/metabolism
9.
Phytomedicine ; 21(6): 800-6, 2014 May 15.
Article in English | MEDLINE | ID: mdl-24629599

ABSTRACT

We previously demonstrated that ethyl acetate extracts of Kaempferia parviflora Wall. Ex Baker (KPE) improve insulin resistance in TSOD mice and showed that its components induce differentiation and adipogenesis in 3T3-L1 preadipocytes. The present study was undertaken to examine whether KPE and its isolated twelve components suppress further lipid accumulation in 3T3-L1 mature adipocytes. KPE reduced intracellular triglycerides in mature adipocytes, as did two of its components, 3,5,7,3',4'-pentamethoxyflavone and 5,7,4'-trimethoxyflavone. Shrinkage of lipid droplets in mature adipocytes was observed, and mRNA expression levels of adipose tissue triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) were up-regulated by these two polymethoxyflavonoids (PMFs). Furthermore, the protein expression level of ATGL and the release level of glycerol into the cell culture medium increased. In contrast, the peroxisome proliferator-activated receptor γ (PPARγ) agonist, troglitazone, did not decrease intracellular triglycerides in mature adipocytes, and the mRNA expression level of PPARγ was not up-regulated in mature adipocytes treated with the two active PMFs. Therefore, suppression of lipid accumulation in mature adipocytes is unlikely to be enhanced by transcriptional activation of PPARγ. These results suggest that KPE and its active components enhance lipolysis in mature adipocytes by activation of ATGL and HSL independent of PPARγ transcription, thus preventing adipocyte hypertrophy. On the other hand, the full hydroxylated flavonoid quercetin did not show the suppressive effects of lipid accumulation in mature adipocyte in the same conditions. Consequently, methoxy groups in the flavones are important for the activity.


Subject(s)
Adipocytes/drug effects , Adipogenesis/drug effects , Flavonoids/pharmacology , Plant Extracts/pharmacology , Triglycerides/metabolism , Zingiberaceae/chemistry , 3T3-L1 Cells , Adipocytes/metabolism , Adipocytes/pathology , Animals , Flavones/pharmacology , Hypertrophy , Lipase/metabolism , Lipolysis , Mice , PPAR gamma/genetics , PPAR gamma/metabolism , RNA, Messenger/metabolism
10.
Nat Prod Commun ; 9(9): 1291-4, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25918795

ABSTRACT

The SIRT1 enzyme-stimulating and anti-glycation activities of Kaempferia parviflora extract and its main polymethoxyflavonoids were evaluated in vitro. K. parviflora extract elevated SIRT1 catalytic activity by eight- and 17-fold at 20 µg/mL and 100 µg/mL, respectively, compared with vehicle only. Two major polymethoxyflavonoids, 3,5,7,3',4'-pentamethoxyflavone (4) and 5,7,4'-trimethoxyflavone (5), were isolated from this extract and are four- and fivefold more potent than resveratrol, hitherto the strongest known natural SIRT1 activator. In addition, the anti-glycation activity of K. parviflora extract was observed to be seven times more effective than aminoguanidine, a clinical anti-diabetes drug. 3,5,7,3',4'-Pentamethoxyflavone (4) and 5,7,4'-trimethoxyflavone (5) showed the strongest anti-glycation activity among the tested polymethoxyflavonoids. Further comparison of the activity of these structurally related polymethoxyflavonoids revealed a possible structure-activity relationship, in particular, for the contribution of methoxy moieties.


Subject(s)
Flavonoids/chemistry , Plant Extracts/chemistry , Sirtuin 1/metabolism , Zingiberaceae/chemistry , Enzyme Activation/drug effects , Glycosylation/drug effects , Humans , Kinetics , Sirtuin 1/chemistry
11.
Aging Cell ; 12(1): 50-7, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23072361

ABSTRACT

Aging is accelerated, at least in part, by pathological condition such as metabolic syndrome (MetS), and various molecular pathways such as oxidative stress are common mediators of aging and MetS. We previously developed the aging-like skin model by single ultraviolet (UV) irradiation on the MetS model mice. Recent studies revealed that mineralocorticoid receptor (MR) signaling plays a pivotal role for various tissue inflammation and damages in MetS. Although previous studies reported that MR is expressed in the skin and that overexpression of MR in the skin resulted in the skin atrophy, the physiological or pathological functions of MR in the skin are not fully elucidated. Here, we show the involvement of MR signaling in the aging-like skin changes in our own model. Elevations of oxidative stress and inflammation markers were observed in the MetS mice, and the UV-evoked aging-like skin damages were attenuated by topical antioxidant. MR expression was higher in the MetS mouse skin, and notably, expression of its effecter gene Sgk1 was significantly upregulated in the aging-like skin in the UV-irradiated MetS mice. Furthermore, topical application of MR antagonist spironolactone suppressed Sgk1 expression, oxidative stress, inflammation, and the aging-like changes in the skin. The 2-week UV onto the non-MetS mice, the more usual photoaging model, resulted in the skin damages mostly equivalent to the MetS mice with single UV, but they were not associated with upregulation of MR signaling. Our studies suggested an unexpected role of MR signaling in the skin aging in MetS status.


Subject(s)
Metabolic Syndrome/metabolism , Receptors, Mineralocorticoid/metabolism , Skin Aging , Skin Diseases/pathology , Skin/metabolism , Animals , Disease Models, Animal , Male , Metabolic Syndrome/pathology , Mice , Oxidative Stress , Signal Transduction , Skin/pathology , Skin Diseases/metabolism
12.
Lab Invest ; 93(2): 230-41, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23212097

ABSTRACT

Metabolic syndrome is a worldwide healthcare issue and a dominant risk factor for the development of incurable diseases that affect the entire body. The hepatic manifestations of this syndrome include nonalcoholic fatty liver disease (NAFLD) and its progressive variant nonalcoholic steatohepatitis (NASH). The basic pathogenesis of NAFLD/NASH remains controversial because it is difficult to clarify the disease process of NASH on the basis of metabolic syndrome alone. To determine the pathogenesis and effective treatment, an excellent animal model of NASH is required. Tsumura Suzuki obese diabetes (TSOD) male mice spontaneously develop diabetes mellitus, obesity, glucosuria, hyperglycemia, and hyperinsulinemia without any special treatments such as gene manipulation. In this study, we examined the histopathological characteristics of visceral fat and liver of 56 male TSOD mice aged 4-17 months and 9 male Tsumura Suzuki non-obesity (control) mice aged 6-12 months. In the visceral fat, enlargement of adipocytes and perivascular and pericapsular CD8-positive lymphoid aggregation were observed in 4-month-old mice. Abnormal expression of tumor necrosis factor-α, interleukin-6, and lipid peroxidation endo products was observed in macrophages. In the liver, microvesicular steatosis, hepatocellular ballooning, and Mallory bodies were observed in 4-month-old mice, with severity worsening with increasing time. These pathological findings in the liver mimic those seen in patients with NASH. Interestingly, small liver nodules with high cellularity and absence of portal tracts were frequently observed after 12 months. Most of them showed nuclear and structural atypia, and mimicked human hepatocellular carcinoma. The degree of steatosis in the non-tumor portions of the liver improved when the liver nodules developed. These findings were not observed in control mice. Here, we report that TSOD male mice spontaneously developed NAFLD without any special treatment, and that these mice are a valuable model for assessing NASH and NASH carcinogenesis owing to metabolic syndrome.


Subject(s)
Carcinoma, Hepatocellular/etiology , Disease Models, Animal , Fatty Liver/etiology , Fatty Liver/physiopathology , Liver Neoplasms/etiology , Metabolic Syndrome/complications , Animals , CD8-Positive T-Lymphocytes/immunology , Carcinoma, Hepatocellular/physiopathology , Immunohistochemistry , Interleukin-6/metabolism , Intra-Abdominal Fat/pathology , Lipid Peroxidation , Liver/pathology , Liver Neoplasms/physiopathology , Male , Mice , Mice, Obese , Non-alcoholic Fatty Liver Disease , Tumor Necrosis Factor-alpha/metabolism
13.
Biol Pharm Bull ; 35(10): 1765-74, 2012.
Article in English | MEDLINE | ID: mdl-23037166

ABSTRACT

One of the mediators of osteoclast differentiation is receptor activator of nuclear factor κB ligand (RANKL), which is produced by osteoblasts. Binding of RANKL to its receptor, RANK, activates several signaling pathways, including those involving mitogen-activated protein kinases (MAPKs), nuclear factor κB (NF-κB), nuclear factor of activated T cells c1 (NFATc1) and Ca(2+)-calcineurin. In the present study, we found that tetrandrine, a bisbenzylisoquinoline alkaloid extracted from the root of Stephania tetrandra S. MOORE, significantly ameliorated the decrease of bone mass in sciatic-neurectomized osteoporosis model mice. It appears that tetrandrine acts directly on osteoclast precursors, since tetrandrine inhibited osteoclast differentiation not only in mouse bone marrow cells, but also in monocultures of murine macrophage RAW 264.7 cells without osteoblasts. Tetrandrine suppressed RANKL-induced amplification of NFATc1, a master regulator of osteoclast differentiation. However, it did not affect other signaling molecules such as MAPKs and NF-κB. These results suggest that tetrandrine is a candidate for the treatment of bone-destructive diseases, or at least a suitable lead compound for further development.


Subject(s)
Benzylisoquinolines/therapeutic use , Bone Resorption/prevention & control , Cell Differentiation/drug effects , Osteoclasts/cytology , Receptor Activator of Nuclear Factor-kappa B/pharmacology , Animals , Benzylisoquinolines/pharmacology , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Cell Line , Cells, Cultured , Drugs, Chinese Herbal , Male , Mice , NFATC Transcription Factors/metabolism , Sciatic Nerve/surgery
14.
Biol Pharm Bull ; 35(5): 686-92, 2012.
Article in English | MEDLINE | ID: mdl-22687402

ABSTRACT

We previously reported that Kaempferia parviflora WALL. ex BAKER (KP) and its ethyl acetate extract (KPE) improve various metabolic disorders in obesity-model mice. However the mechanism is not certain, and, in this study, in order to elucidate the mechanism of the suppressive effect of KP on fat accumulation, we focused on adipocytes, which are closely linked to metabolic diseases. The finding was that KPE and its components, 3,5,7,4'-tetramethoxyflavone and 3,5,7,3',4'-pentamethoxyflavone, strongly induced differentiation of 3T3-L1 preadipocytes to adipocytes. The above two polymethoxyflavonoids (PMFs) also induced adiponectin mRNA levels, and release of adiponectin into the medium. In addition, these PMFs enhanced the expression of peroxisome proliferator-activated receptor γ (PPARγ), but did not show PPARγ ligand activity. We then investigated the expression of the differentiation-regulator located upstream of PPARγ. Expression of CCAAT/enhancer-binding protein (C/EBP) ß and -δ mRNA, a transcriptional regulator of PPARγ, was induced, and expression of GATA-2 mRNA, a down-regulator of adipogenesis, was suppressed by these PMFs. These functions of the KP PMFs that enhance adipogenesis and secretion of adiponectin are, to some extent at least, involved in the mechanisms of anti-metabolic disorders effects.


Subject(s)
Adipocytes/drug effects , Adipogenesis/drug effects , Flavones/pharmacology , Lipid Metabolism/drug effects , Plant Extracts/pharmacology , Transcription Factors/metabolism , Zingiberaceae/chemistry , 3T3-L1 Cells , Adipocytes/cytology , Adipocytes/metabolism , Adipogenesis/genetics , Adiponectin/genetics , Adiponectin/metabolism , Animals , CCAAT-Enhancer-Binding Protein-alpha/genetics , CCAAT-Enhancer-Binding Protein-alpha/metabolism , CCAAT-Enhancer-Binding Protein-beta/genetics , CCAAT-Enhancer-Binding Protein-beta/metabolism , GATA Transcription Factors/genetics , GATA Transcription Factors/metabolism , Lipid Metabolism/genetics , Metabolic Diseases/genetics , Metabolic Diseases/metabolism , Mice , PPAR gamma/metabolism , RNA, Messenger/metabolism , Transcription Factors/genetics
15.
Article in English | MEDLINE | ID: mdl-22685484

ABSTRACT

Kudzu, a leguminous plant, has long been used in folk medicine. In particular, its flowers are used in Japanese and Chinese folk medicine for treating hangovers. We focused on the flower of Kudzu (Puerariae thomsonii), and we previously reported the antiobesity effect of Puerariae thomsonii flower extract (PFE) in humans. In this study, we conducted an animal study to investigate the effect of PFE on visceral fat and hepatic lipid levels in mice with diet-induced obesity. In addition, we focused on gene expression profiles to investigate the antiobesity mechanism of PFE. Male C57BL/6J mice were fed a high-fat diet (HFD) or an HFD supplemented with 5% PFE for 14 days. PFE supplementation significantly reduced body weight and white adipose tissue (WAT) weight. Moreover, in the histological analysis, PFE supplementation improved fatty liver. Hepatic reverse transcription-polymerase chain reaction revealed that PFE supplementation downregulated acetyl-CoA carboxylase expression. For adipose tissue, the expressions of hormone-sensitive lipase in WAT and uncoupling protein 1 in brown adipose tissue (BAT) were significantly upregulated. These results suggest that PFE exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice through suppressing lipogenesis in the liver, stimulating lipolysis in WAT, and promoting thermogenesis in BAT.

16.
J Nat Med ; 66(4): 622-30, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22350143

ABSTRACT

Puerariae flos extract (PFE) has been reported to have many effects, including preventing the development of hangovers, liver protective effects, and an estrogenic effect. In addition, some papers reported that PFE is effective against metabolic diseases, with hypolipidemic and hypoglycemic effects. However, the mechanism underlying such effects remains unclear. For the purpose of clarifying the effect of PFE on metabolic diseases related to the accumulation of visceral fat and to determine the mechanism of such action, TSOD mice, a multifactorial genetic disease animal model that spontaneously develops various metabolic diseases such as obesity and type 2 diabetes, were given a Western diet (WTD) as an environmental factor to prepare a disease model (TSOD-WTD). When TSOD mice were loaded with WTD, it was confirmed that metabolic diseases such as obesity and abnormal glucose/lipid metabolism are aggravated. In contrast, PFE treatment to TSOD-WTD mice was shown to suppress body weight gain and visceral fat accumulation, alleviated the abnormal glucose tolerance and hyperinsulinemia, as well as causing an increase in blood adiponectin. Furthermore, the suppression of liver enlargement was observed in PFE-treated mice, with suppression of fatty degeneration and anti-inflammatory effect. In addition, to clarify the mechanism of the hyperlipidemia-alleviating effects in the liver, we investigated the effect of PFE on the expression of genes involved in cholesterol homeostasis. PFE was associated with a significant increase in gene expression for cholesterol synthesis rate-limiting enzyme HMG-CoA reductase, cholesterol catabolization enzyme Cyp7A1, bile salt export pump adenosine triphosphate-binding cassette transporter B11, and low-density lipoprotein receptor involved in cholesterol uptake. The above results suggest that PFE acts to alleviate the effects of various metabolic diseases based on the accumulation of visceral adipose tissue, including obesity, diabetes, and hyperlipidemia, with the promotion of catabolization/excretion of cholesterol in the liver being a key mechanism of action.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diet, High-Fat/adverse effects , Metabolic Diseases/drug therapy , Obesity/drug therapy , Plant Extracts/therapeutic use , Pueraria/chemistry , Animals , Cholesterol/blood , Diabetes Mellitus, Type 2/blood , Glucose Tolerance Test , Metabolic Diseases/blood , Mice , Obesity/blood , Plant Extracts/chemistry , Polymerase Chain Reaction
17.
Biol Pharm Bull ; 35(2): 171-7, 2012.
Article in English | MEDLINE | ID: mdl-22293346

ABSTRACT

Oxidative damage and inflammation are implicated in the pathogenesis of liver injury and fibrosis. In the present study, we investigated the molecular mechanism by which gomisin A conferred a hepatoprotective effect, focusing on its antioxidant and anti-inflammatory effects using rats with carbon tetrachloride (CCl(4))-induced acute liver injury. Pretreatment with gomisin A prior to the administration of CCl(4) markedly prevented an increase in alanine aminotransferase, aspartate aminotransferase, and histological hepatic lesions. Gomisin A was also associated with a decrease in hepatic lipid peroxidation, and increased superoxide dismutase activity, suggesting that gomisin A has an antioxidant effect. In addition gomisin A treatment ameliorated mRNA levels of CCl(4)-induced inflammatory mediators, including tumor necrosis factor-α, interleukin-1ß and inducible nitric oxide (NO) synthase, and the protein levels of transcriptional upregulator nuclear factor kappa B (NF-κB) and phospho-inhibitor of NF-κB (IκB). Furthermore, α-smooth muscle actin (α-SMA), a myofibroblast marker, was also inhibited by gomisin A treatment. These results suggest that gomisin A inhibits the oxidative stress and activation of NF-κB, leading to down-regulation of pro-inflammatory mediators and amelioration of fibrogenesis.


Subject(s)
Chemical and Drug Induced Liver Injury/drug therapy , Cyclooctanes/therapeutic use , Dioxoles/therapeutic use , Lignans/therapeutic use , NF-kappa B/metabolism , Oxidative Stress/drug effects , Protective Agents/therapeutic use , Actins/genetics , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Carbon Tetrachloride/adverse effects , Chemical and Drug Induced Liver Injury/metabolism , Cyclooctanes/pharmacology , Dioxoles/pharmacology , Interleukin-1beta/genetics , Lignans/pharmacology , Lipid Peroxidation/drug effects , Male , Malondialdehyde/metabolism , Nitric Oxide Synthase Type II/genetics , Protective Agents/pharmacology , RNA, Messenger/metabolism , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolism , Tumor Necrosis Factor-alpha/genetics
18.
Eur J Pharmacol ; 677(1-3): 147-53, 2012 Feb 29.
Article in English | MEDLINE | ID: mdl-22227333

ABSTRACT

Flavangenol, one of several pine bark extract products, is expected to prevent metabolic diseases with its potent antioxidant effect, its anti-obesity effect and its improvement of insulin sensitivity. In this study, targeting the liver as one of the organs that plays an important role in energy metabolism, Flavangenol was investigated for its effect on non-alcoholic fatty liver disease (NAFLD), its action mechanism and its active ingredients, using in vivo and in vitro experiment systems. Flavangenol suppressed intrahepatic fat accumulation in Western diet-loaded Tsumura Suzuki Obese Diabetes (TSOD) mice, which develop various metabolic diseases. In addition, Flavangenol significantly increased the mRNA expression levels of fatty acid oxidative enzymes (peroxisomal proliferator-activated receptor α, acyl-CoA oxidase, carnitine palmitoyltransferase). In order to investigate the direct effect of Flavangenol on the liver, an in vitro fatty liver model prepared by adding a free fatty acid to human liver cancer cells (HepG2 cells) was used. In this model, Flavangenol significantly suppressed intracellular fat accumulation. Procyanidin B1, one of the major components of Flavangenol, also suppressed fat accumulation and induced mRNA expression of the fatty acid oxidative enzymes. As mentioned above, Flavangenol showed a significant suppressive effect in the NAFLD model, and it was suggested that the molecular mechanism is induction of fatty acid oxidation, with the effect mainly attributed to procyanidin B1.


Subject(s)
Biflavonoids/chemistry , Biflavonoids/pharmacology , Catechin/pharmacology , Disease Models, Animal , Fatty Acids/metabolism , Fatty Liver/metabolism , Proanthocyanidins/chemistry , Proanthocyanidins/pharmacology , Animals , Diabetes Mellitus/metabolism , Fatty Liver/diagnostic imaging , Fatty Liver/pathology , Fatty Liver/physiopathology , Gene Expression Regulation, Enzymologic/drug effects , Hep G2 Cells , Humans , Lipid Metabolism/drug effects , Liver/drug effects , Liver/metabolism , Liver/pathology , Liver/physiopathology , Liver Function Tests , Male , Mice , Non-alcoholic Fatty Liver Disease , Obesity/metabolism , Oxidation-Reduction/drug effects , Pinus/chemistry , Plant Bark/chemistry , Plant Extracts/chemistry , Plant Extracts/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tomography, X-Ray Computed
19.
J Nat Med ; 66(2): 329-32, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22005830

ABSTRACT

Near-infrared (NIR) spectroscopy combined with chemometrics has been utilized in predictions of natural medicine content without destroying samples. Suppositories (oren powdered extract content 0, 0.5, 1.0, 2.5, 10, 12.5, and 15%) were produced by mixing oren powdered extract with macrogol mixture consisting of 1 part macrogol 1500 and 2.5 parts macrogol 4000 at 54°C, and pouring the melt mixture into a plastic container. NIR spectra of the 10 prepared samples were recorded 10 times, and a total of 100 spectra were randomly divided into two data sets, one for calibration and the other for validation. The calibration model for the oren content of the suppository was calculated based on NIR spectra using a partial least-squares regression analysis after pre-treatment (smoothing and the multiplicative scatter correction). The relationship between the actual and predicted values for calibration and validation models had a straight line with correlation coefficients of 0.9936 and 0.9898, respectively. The regression vector result of the calibration model indicates that the peaks at 6945, 5747, and 5160 cm(-1) in the regression vector were consistent with those in oren powder extracts. NIR spectroscopy combined with chemometrics offers promise as a method of predicting the oren powder content in suppositories without destroying the samples.


Subject(s)
Coptis/chemistry , Plant Extracts/analysis , Spectroscopy, Near-Infrared/methods , Suppositories/chemistry , Herbal Medicine
20.
Exp Dermatol ; 21(3): 178-83, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22171591

ABSTRACT

The purpose of this study was to test the hypothesis that obese diabetic mice exhibit marked skin fragility, which is caused by increased oxidative stress and increased matrix metalloproteinase (MMP) gene expression in the subcutaneous adipose tissue. Scanning electron microscopy of skin samples from Tsumura-Suzuki obese diabetic (TSOD) mice revealed thinner collagen bundles, and decreased density and convolution of the collagen fibres. Furthermore, skin tensile strength measurements confirmed that the dorsal skin of TSOD mice was more fragile to tensile force than that of non-obese mice. The mRNA expressions of heme oxygenase 1 (Hmox1), a marker of oxidative stress, Mmp2 and Mmp14 were increased in the adipose tissue of TSOD mice. Antioxidant experiments were subsequently performed to determine whether the changes in collagen fibres and skin fragility were caused by oxidative stress. Strikingly, oral administration of the antioxidant dl-α-tocopherol acetate (vitamin E) decreased Hmox1, Mmp2 and Mmp14 mRNA expressions, and improved the skin tensile strength and structure of collagen fibres in TSOD mice. These findings suggest that the skin fragility in TSOD mice is associated with dermal collagen damage and weakened tensile strength, and that oxidative stress and MMP overexpression in the subcutaneous adipose tissue may, at least in part, affect dermal fragility via a paracrine pathway. These observations may contribute to novel clinical interventions, such as dietary supplementation with antioxidants or application of skin cream containing antioxidants, which may overcome skin fragility in obese patients with diabetes.


Subject(s)
Diabetes Mellitus/metabolism , Matrix Metalloproteinases/metabolism , Obesity/metabolism , Oxidative Stress/physiology , Skin/physiopathology , Subcutaneous Fat/metabolism , Up-Regulation/physiology , Animals , Disease Models, Animal , Fibrillar Collagens/ultrastructure , Gene Expression Profiling , Male , Matrix Metalloproteinases/genetics , Mice , Mice, Obese , Microscopy, Electron, Scanning , Real-Time Polymerase Chain Reaction , Skin/metabolism , Tensile Strength/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...